• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

85.34 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 533
Open 85.34
Bid (Size) 45.00 (600)
Ask (Size) 87.91 (400)
Prev. Close 85.34
Today's Range 85.34 - 85.34
52wk Range 16.64 - 96.50
Shares Outstanding 60,648,883
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
May 13, 2026
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
May 13, 2026
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance

Performance

YTD
+115.1%
+115.1%
1 Month
-10.1%
-10.1%
3 Month
+79.7%
+79.7%
6 Month
+140.4%
+140.4%
1 Year
+351.5%
+351.5%

More News

Read More
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
May 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 05, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗
April 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗
April 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Via Finterra
Topics Economy
News headline image
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
March 10, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 09, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
March 09, 2026
Via Stocktwits
Gapping stocks in Monday's session ↗
March 09, 2026
Via Chartmill
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
March 09, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
March 09, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
March 08, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
February 24, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
February 23, 2026
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗
January 07, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
December 23, 2025
From Dianthus Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
The current price of Dianthus Therapeutics, Inc. - Common Stock is 85.34
When was Dianthus Therapeutics, Inc. - Common Stock last traded?
The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 05/14/26 04:00 PM ET
What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?
The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 5.18B
How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?
Dianthus Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap